Young Adults With NSCLC More Apt to Get Advanced Disease Diagnosis
VIENNA — Younger adults (ages under 50) with non-small cell lung cancer (NSCLC) were significantly more likely than older adults to be diagnosed with advanced disease, a researcher said here. In 2018, 5 years after the U.S. Preventive Services Task Force recommended low-dose CT lung cancer screening (LCS) for people over age 55 — lowered […]
KRAS Inhibitor Shrinks Tumors in Over 40% of NSCLC Patients
CHICAGO — More than 40% of patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC) responded to treatment with adagrasib, findings from a phase II trial showed. Among 112 evaluable patients in the KRYSTAL-1 study, all of whom were previously treated, the confirmed objective response rate (ORR) was 42.9% with the investigational KRAS G12C inhibitor, […]
Targeted drug achieves 43% response rate in KRAS-mutated lung cancer: Experimental drug adagrasib also shows activity in lung cancer metastases to the brain
Nearly 43% of patients with non-small cell lung cancer (NSCLC) whose lung cancers harbored a specific KRAS mutation responded to the experimental drug adagrasib, and the targeted agent also showed activity against lesions in the brain that metastasized from the lung tumors, according to results of a study led by Dana-Farber Cancer Institute investigators. Mutations […]
Another Possible Option for HER2-Mutated Non-Small Cell Lung Cancer
More than half of patients with treatment-refractory HER2-positive non-small cell lung cancer (NSCLC) responded to an anti-HER2 antibody-drug conjugate, data from a preliminary trial showed. Fifty of 91 patients responded to trastuzumab deruxtecan (T-DXd) and another 34 patients had stable disease, resulting in a disease control rate exceeding 90%. Responses were durable in many cases, […]
Immuno-Oncology Combo Active in Recurrent EGFR/ALK Positive NSCLC
Patients with recurrent EGFR/ALK-positive non-small cell lung cancer (NSCLC) obtained durable remissions with the combination of pembrolizumab (Keytruda) and chemotherapy, a small prospective study showed. The immuno-oncology (IO) combination led to a median progression-free survival (PFS) of 8.3 months in EGFR-mutant NSCLC and overall survival (OS) of 22.2 months. The combination had limited activity in […]